Genta initiates Tesetaxel clinical trial in Japan

June 2011
Worldwide Biotech;Jun2011, Vol. 23 Issue 6, p1
Trade Publication
The article reports on the move by the New Jersey-based firm Genta Inc. to start a new clinical trial of the oral drug tesetaxel against advanced cancer in Japan. According to Genta's Doctor Loretta M. Itri, the trial shows the firm's deep cooperation with Japan's Pharmaceuticals and Medical Devices Agency (PMDA) and other Japanese investigators. The study will be carried out at Kinki University in Osaka, Japan.


Related Articles

  • Genta reports studies showing afficacy of multiple myeloma drug.  // PharmaWatch: Cancer;July 2003, Vol. 2 Issue 7, p35 

    Reports that studies show that Genta's antisense drug that targets cancer cells boosts the effectiveness of chemotherapy in patients with multiple myeloma. Preclinical studies showing that the initiation of myeloma cell death by standard chemotherapy was blocked by Bcl-2, the target of Genasense...

  • Genta begins study of Genasense in patients with advanced breast cancer.  // PharmaWatch: Cancer;July 2003, Vol. 2 Issue 7, p7 

    Reports that Genta has initiated a clinical trial with its lead anticancer drug, Genasense, in patients with advanced breast cancer. Evaluation of the safety and efficacy of Genasense in combination with Aventis' Taxotere and doxorubicin, two standard chemotherapy drugs; Mechanism of action of...

  • Could less be more? Low-dose chemotherapy goes on trial. Garber, Ken // JNCI: Journal of the National Cancer Institute;1/16/2002, Vol. 94 Issue 2, p82 

    Focuses on the clinical trial on the effect of low-dose chemotherapy to drug-resistant tumors. Idea of Judah Folkman, Doctor of Medicine (M.D.) on low-dose chemotherapy; Administration of metronomic chemotherapy assay; Comment of Barton Kamen, M.D., Doctor of Philosophy, of the Cancer Institute...

  • San Antonio Breast Cancer Symposium.  // BioWorld Today;12/9/2011, Vol. 22 Issue 237, p5 

    The article deals with the results presented by Genta Inc. at the 2011 San Antonio Breast Cancer Symposium from a Phase IIb trial of single-agent tesetaxel in advanced breast cancer patients.

  • Genta initiates treatment in Phase II melanoma trial.  // PharmaWatch: Biotechnology;Mar2010, Vol. 9 Issue 3, p4 

    The article reports that the biotechnology company Genta Inc. has started treatment of the first subject in a new Phase II trial of tesetaxel in advanced melanoma.

  • Trials in progress.  // Applied Clinical Trials;Nov2003, Vol. 12 Issue 11, p14 

    No abstract available.

  • Genta Plunges on Failed Phase III Survival Analysis for Genasense. Morrison, Trista // BioWorld Today;5/24/2011, Vol. 22 Issue 100, p2 

    The article reports on the decision of Genta Inc. to hold further work with its antisense drug Genasense. Their decision was influenced by the fact that Genasense failed to improve overall survival in the final analysis of the AGENDA Phase III melanoma trial. The company announced that it will...

  • Clinic Roundup.  // BioWorld Today;5/9/2012, Vol. 23 Issue 90, p8 

    This section offers news briefs concerning several clinical trials in the biotechnology sector, as of May 2012. Two new patients were enrolled in a Phase I/II study of Advaxis Inc. sponsored by Cancer Research UK to test immunotherapy candidates ADXS-HPV for the treatment of human papillomavirus...

  • Genta: Genasense Phase III melanoma trial gets go-ahead.  // PharmaWatch: Monthly Review;Jul2009, Vol. 8 Issue 7, p10 

    The article reports on the announcement by an independent Data Monitoring Board concerning the continuation of a Phase III trial of Genta Inc.'s Genasense in advance melanoma in the U.S. According to reports, the Genasense passed the final futility analysis of progression-free survival (PFS)...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics